Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)
Historic Gross Margin for Avalo Therapeutics (AVTX) over the last 8 years, with Q3 2024 value amounting to 186.75%.
- Avalo Therapeutics' Gross Margin fell 1820900.0% to 186.75% in Q3 2024 from the same period last year, while for Sep 2024 it was 11.71%, marking a year-over-year decrease of 172200.0%. This contributed to the annual value of 33.26% for FY2023, which is 477100.0% down from last year.
- According to the latest figures from Q3 2024, Avalo Therapeutics' Gross Margin is 186.75%, which was down 1820900.0% from 138.7% recorded in Q4 2023.
- Over the past 5 years, Avalo Therapeutics' Gross Margin peaked at 138.7% during Q4 2023, and registered a low of 186.75% during Q3 2024.
- Over the past 5 years, Avalo Therapeutics' median Gross Margin value was 32.74% (recorded in 2021), while the average stood at 19.32%.
- As far as peak fluctuations go, Avalo Therapeutics' Gross Margin surged by 1244100bps in 2022, and later crashed by -1820900bps in 2024.
- Avalo Therapeutics' Gross Margin (Quarter) stood at 63.33% in 2020, then crashed by -248bps to 93.61% in 2021, then skyrocketed by 133bps to 30.8% in 2022, then surged by 350bps to 138.7% in 2023, then crashed by -235bps to 186.75% in 2024.
- Its Gross Margin was 186.75% in Q3 2024, compared to 138.7% in Q4 2023 and 4.66% in Q3 2023.